RAD18 is a key factor contributing to increased resistance to radio/chemotherapy in several cancers (Xie et al, 2014; Wu et al, 2019; Li et al, 2022; Du et al, 2022), therefore it is of high therapeutic interest to inhibit RAD18 in these scenarios. This evidence concerns the gene RAD18 and cancer.